



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 137889

TO: Kevin Weddington
Location: rem/3a65/3c70
Art Unit: 1614
Wednesday, November 24, 2004

Case Serial Number: 10/806088

From: Peggy Ruppel
Location: Biotech-Chem Library
REMSSEN 1B65
Phone: 571-272-2557

Peggy.Ruppel@uspto.gov

Search Notes

I limited the number of databases I searched because I found such good art so quickly.

Please contact me if you have any questions or comments.

Thank you for using STIC services.



REM-3070

Access DB# 137889

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: K. Weddington Examiner #: 68082 Date: 11-15-04
Art Unit: 1614 Phone Number: 301-272-0587 Serial Number: 101806, 088
Mail Box and Bldg/Room Location: REM-3A65 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Treating cancer with (-) gossypol

RECEIVED
NOV 16 2004
STIC

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbi: _____
Date Searcher Picked Up: <u>11-24-04</u>	Bibliographic _____	Dr. Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

=> b reg

FILE 'REGISTRY' ENTERED AT 13:26:52 ON 24 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2004 HIGHEST RN 786612-66-6
DICTIONARY FILE UPDATES: 22 NOV 2004 HIGHEST RN 786612-66-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que l1

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON "(-)-GOSSYPOL"/CN

=> d ide l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 90141-22-3 REGISTRY
CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-
3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-
3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (R)-
OTHER NAMES:
CN (-)-Gossypol
CN (R)-(-)-Gossypol
CN (R)-Gossypol
MF C30 H30 O8
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS,
CASREACT, IPA, MRCK*, NAPRALERT, PROMT, RTECS*, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)
DT.CA Caplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

111 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

112 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b home

FILE 'HOME' ENTERED AT 13:27:06 ON 24 NOV 2004

=>

=> b hcaplus

FILE 'HCAPLUS' ENTERED AT 13:25:48 ON 24 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Nov 2004 VOL 141 ISS 22
FILE LAST UPDATED: 23 Nov 2004 (20041123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que l30

L27 (19)SEA FILE=HCAPLUS ABB=ON PLU=ON ("FLACK M"/AU OR "FLACK M R"/AU) OR ("FLACK MARY"/AU OR "FLACK MARY R"/AU)
L28 (45)SEA FILE=HCAPLUS ABB=ON PLU=ON ("KNAZEK R"/AU OR "KNAZEK R A"/AU OR "KNAZEK RICHARD"/AU OR "KNAZEK RICHARD A"/AU OR "KNAZEK RICHARD ALLAN"/AU)
L29 (144)SEA FILE=HCAPLUS ABB=ON PLU=ON ("REIDENBERG M"/AU OR "REIDENBERG M M"/AU OR "REIDENBERG MARCUS"/AU OR "REIDENBERG MARCUS M"/AU) OR "REIDENBERN MARCUS M"/AU
L30 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L27 AND L28 AND L29

=> d all l30

L30 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:485409 HCAPLUS
DN 115:85409
ED Entered STN: 06 Sep 1991
TI Gossypol and related compounds for the treatment of cancer
IN **Flack, Mary R.; Knazek, Richard; Reidenberg, Marcus**
PA National Institutes of Health, USA
SO U. S. Pat. Appl., 20 pp. Avail. NTIS Order No. PAT-APPL-7-551 353.
CODEN: XAXXAV
DT Patent
LA English
CC 1-6 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 551353	A0	19910415	US 1990-551353	19900712
	US 5385936	A	19950131		
	US 6114397	A	20000905	US 1995-379872	19950127

Searched by P. Ruppel

PRAI US 1990-551353 A3 19900712

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 551353

AB Gossypol (I) and related compds. are provided as antitumor agents effective against human cancers. In a study of the effect of I on SW-13 tumor-bearing nude mice, tumor prevalence had dropped from 71 to 54% after 12 wk in the treatment group, while tumor prevalence had risen in the control group; there was no significant effect on body wts. During the study period, 8.3 and 41.6%, resp., of I-treated and control animals died. Preliminary results of I treatment in a clin. trial with metastatic adrenocortical carcinoma patients are also given.

ST gossypol neoplasm inhibitor; metastatic adrenocortical carcinoma inhibitor gossypol

IT Neoplasm inhibitors
(gossypol)

IT Adrenal cortex, neoplasm
(carcinoma, treatment of, with gossypol)

IT Neoplasm inhibitors
(carcinoma, metastasis, adrenocortical, gossypol)

IT 303-45-7, Gossypol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibitor)

=> => b home

FILE 'HOME' ENTERED AT 13:26:30 ON 24 NOV 2004

=>

=> b hcaplus

FILE 'HCAPLUS' ENTERED AT 13:23:59 ON 24 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Nov 2004 VOL 141 ISS 22

FILE LAST UPDATED: 23 Nov 2004 (20041123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que 118

L12 (1)SEA FILE=REGISTRY ABB=ON PLU=ON "(-)-GOSSYPOL"/CN
L13 (112)SEA FILE=HCAPLUS ABB=ON PLU=ON L12
L14 (323433)SEA FILE=HCAPLUS ABB=ON PLU=ON NEOPLASM?/CT,CW
L15 (188471)SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTITUMOR AGENTS"+OLD,NT/CT
L16 (478254)SEA FILE=HCAPLUS ABB=ON PLU=ON ?CANCER?/BI OR L14 OR L15
L17 (20)SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND L16
L18 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (PRY<=1990 OR
PY<=1990 OR AY<=1990)

=> b medl

FILE 'MEDLINE' ENTERED AT 13:24:08 ON 24 NOV 2004

FILE LAST UPDATED: 23 NOV 2004 (20041123/UP). FILE COVERS 1950 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details.

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 125

L19 (744)SEA FILE=MEDLINE ABB=ON PLU=ON GOSSYPOL/CT(L) (PD OR TU OR PK
OR AD)
L20 (610746)SEA FILE=MEDLINE ABB=ON PLU=ON "ANTINEOPLASTIC AGENTS"+NT/CT

Mitochondria: EN, enzymology
 Oncogenes
 Protein Kinase C: ME, metabolism
 RNA, Messenger: DE, drug effects
 Stereoisomerism
 Tumor Cells, Cultured
 beta 2-Microglobulin: BI, biosynthesis
 beta 2-Microglobulin: GE, genetics
 RN 303-45-7 (Gossypol)
 CN 0 (Antineoplastic Agents); 0 (Calmodulin); 0 (Heat-Shock Proteins); 0
 (Isoenzymes); 0 (RNA, Messenger); 0 (beta 2-Microglobulin); EC 2.5.1.18
 (Glutathione Transferase); EC 2.7.1.37 (Protein Kinase C)

L26 ANSWER 2 OF 19 MEDLINE on STN
 ACCESSION NUMBER: 89288013 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 2736516
 TITLE: An in vitro and in vivo study of antitumor effects of
 gossypol on human SW-13 adrenocortical carcinoma.
 AUTHOR: Wu Y W; Chik C L; Knazek R A
 CORPORATE SOURCE: Developmental Endocrinology Branch, National Institute of
 Child Health and Development, Bethesda, Maryland 20892.
 SOURCE: Cancer research, (1989 Jul 15) 49 (14) 3754-8.
 Journal code: 2984705R. ISSN: 0008-5472.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198908
 ENTRY DATE: Entered STN: 19900309
 Last Updated on STN: 19970203
 Entered Medline: 19890803

AB The present study investigated the in vitro and in vivo antitumor effects
 of gossypol on human SW-13 adrenocortical carcinoma cells. In vitro
 gossypol concentrations greater than or equal to 0.5 microM reduced the
 growth rate of the SW-13 cells. Membrane microviscosity was determined by
 fluorescence polarization of diphenylhexatriene. The membranes of viable
 SW-13 cells exposed to gossypol became more rigid after a 1-day exposure
 to gossypol, the polarization constant, P, increasing from 0.229 to 0.352.
 Gossypol also increased the microviscosities of isolated mitochondrial and
 microsomal enriched membrane preparations. Tumor was also transplanted
 into nude mice by s.c. injection of SW-13 cells. A 1-week pretreatment
 period followed by daily administration of gossypol in which 30 mg
 gossypol/kg body weight/day was administered via orogastric tube delayed
 the onset of visible tumor in the subsequent weeks. Five weeks after
 transplantation, tumor prevalence rate was 95.8% in the control group and
 54.5% in the gossypol-treated group. A second experiment, consisting of
 12 weeks of gossypol treatment, reduced a preexisting 71% tumor prevalence
 to 54% while the tumor prevalence increased to 83% in the control group.
 This was accompanied by a 41.6% mortality in the control group versus 8.3%
 in the gossypol-treated group. These data suggest that gossypol may
 provide a beneficial effect in patients with adrenocortical carcinoma.

CT Check Tags: Human; Male; Support, Non-U.S. Gov't
 *Adrenal Cortex Neoplasms: DT, drug therapy
 Adrenal Cortex Neoplasms: PA, pathology
 Animals
 *Antineoplastic Agents
 Cell Division: DE, drug effects
 Cell Line

Cell Membrane: DE, drug effects
Cell Membrane: UL, ultrastructure
Gossypol: PD, pharmacology
*Gossypol: TU, therapeutic use
Mice
Mice, Nude
Microsomes: DE, drug effects
Microsomes: UL, ultrastructure
Mitochondria: DE, drug effects
Mitochondria: UL, ultrastructure
Neoplasm Transplantation
Transplantation, Heterologous
*Tumor Cells, Cultured: CY, cytology
Tumor Cells, Cultured: DE, drug effects
Viscosity

RN 303-45-7 (Gossypol)
CN 0 (Antineoplastic Agents)

L26 ANSWER 3 OF 19 MEDLINE on STN
ACCESSION NUMBER: 89195127 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2539251
TITLE: Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
COMMENT: Erratum in: Cancer Res 1989 Jun 1;49(11):3142
AUTHOR: Adlakha R C; Ashorn C L; Chan D; Zwelling L A
CORPORATE SOURCE: Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
CONTRACT NUMBER: CA-40090 (NCI)
RR5511-23 (NCRR)
SOURCE: Cancer research, (1989 Apr 15) 49 (8) 2052-8.
Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198905
ENTRY DATE: Entered STN: 19900306
Last Updated on STN: 19970203
Entered Medline: 19890524

AB Our earlier studies have shown that gossypol [1,1',6,6',7,7'-hexahydroxy-5,5-diisopropyl - 3,3'-dimethyl - (2,2'-binaphthalene)-8,8'-dicarboxyaldehyde], a male contraceptive, inhibits DNA synthesis by decreasing the activities of DNA polymerase alpha and beta, resulting in the arrest of cells in mid-S phase [L.J. Rosenberg, R.C. Adlakha, D.M. Desai, and P.N. Rao, Biochim. Biophys. Acta, 866: 258-267, 1986]. Now we have examined the effects of gossypol on another enzyme of importance to cellular functions, topoisomerase II (topo II). We have determined the consequences of gossypol treatment on 4'-(9-acridinylamino)methane-sulfon-m anisidide (m-AMSA)-induced topoisomerase II-mediated, protein-associated DNA cleavage using the alkaline elution technique. In HeLa cells pretreated with gossypol (3.4-17.5 microM) for 8-16 h we observed a dose- and time-dependent decrease (50-75%) in DNA cleavage compared to that quantified in cells treated with m-AMSA alone. Gossypol by itself did not induce more than 25 rad-equivalents of DNA single-strand breaks even at the highest dose tested (26 microM). [14C]m-AMSA uptake was identical in treated and untreated cells. Pretreatment of cells with another inhibitor of DNA synthesis, thymidine, which blocks cells at G1/S boundary increased

the m-AMSA-induced DNA cleavage by 25%, suggesting that the effect of gossypol might be due to the arrest of cells in mid-S phase. In contrast to gossypol's effects on m-AMSA-induced DNA cleavage, m-AMSA-induced cytotoxicity was actually increased in gossypol pretreated cells. Gossypol blocked topo II strand passing activity (decatenation of kinetoplast DNA) of cellular extracts from HeLa cells. The inhibition of this activity by gossypol was synergistic with the inhibition produced by m-AMSA or etoposide. These data suggest that gossypol can both inhibit topo II catalytic activity and interfere with the stabilization of topo II-DNA complex formation by m-AMSA. These data indicate that the magnitude of m-AMSA-induced DNA cleavage may not necessarily parallel the magnitude of m-AMSA-induced cytotoxicity. The cytotoxicity data may rather be explained by an action of gossypol and m-AMSA to block topo II catalytic activity at a point in the enzyme's strand passing cycle prior to cleavage complex formation that might be particularly toxic to cells in S phase. Gossypol should therefore be useful in improving our understanding of the cellular role of topo II and the consequences of interference with topo II activity by active antineoplastic agents.

CT Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

*Amsacrine: PK, pharmacokinetics

*Amsacrine: PD, pharmacology

*DNA: DE, drug effects

*DNA Damage

*DNA Topoisomerases, Type I: PH, physiology

*Gossypol: PD, pharmacology

HeLa Cells

RN 303-45-7 (Gossypol); 51264-14-3 (Amsacrine); 9007-49-2 (DNA)

CN EC 5.99.1.2 (DNA Topoisomerases, Type I)

L26 ANSWER 4 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 89280405 EMBASE

DOCUMENT NUMBER: 1989280405

TITLE: The effect of gossypol and 6-aminonicotinamide on tumor cell metabolism: A ³¹P-magnetic resonance spectroscopic study.

AUTHOR: Keniry M.A.; Hollander C.; Benz C.C.

CORPORATE SOURCE: Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia

SOURCE: Biochemical and Biophysical Research Communications, (1989) 164/2 (947-953).

ISSN: 0006-291X CODEN: BBRCA

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 016 Cancer
029 Clinical Biochemistry
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB ³¹P-Magnetic resonance spectroscopy has been used to assess the changes in the levels of water-soluble phosphate pools in T47-D breast carcinoma cells induced by the antimitochondrial drugs, gossypol and 6-aminonicotinamide. A decrease in the NTP/Pi ratio occurred after treatment with gossypol. No change in the NTP/Pi ratio occurred on treatment with 6-aminonicotinamide; however, a substantial accumulation of 6-phosphogluconate was observed. Pretreatment of T47-D cells with gossypol prevented the accumulation of 6-phosphogluconate. This facile and non-invasive approach suggests that the oxidative part of the

(Uses)

(neoplasm inhibiting activity of, in gonadal **cancer**, cell
proliferation inhibition in relation to)

L26 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:504364 HCAPLUS

DOCUMENT NUMBER: 109:104364

TITLE: Gossypol, a cytotoxic agent, may uncouple respiration
of Ehrlich ascites tumor cells

AUTHOR(S): McSheehy, P. M. J.; Bashford, C. L.

CORPORATE SOURCE: Med. Sch., St. George's Hosp., London, SW17 0RE, UK

SOURCE: Biochemical Society Transactions (1988),
16(4), 616-17

CODEN: BCSTB5; ISSN: 0300-5127

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cytotoxic mechanism (I), as a potential antitumor agent, was studied
by evaluating the kinetics of I (9-94 μ M) action on the metabolism of
Ehrlich ascites tumor cells (Lettre cells) by measuring the
phosphorylation potential and O consumption. The results of the study are
not consistent with gossypol acting as a glycolytic inhibitor, but rather
as having an uncoupler-like effect on the cell leading to subsequent cell
lysis and death. The predominantly glycolytic nature of tumor cells, even
under conditions of high O tension, would be likely to make tumors less
sensitive than host tissue to gossypol cytotoxicity. Thus these results
do not correlate with the proposal that gossypol has a role in
chemotherapy.

CC 1-6 (Pharmacology)

IT **Neoplasm inhibitors**

(gossypol in relation to)

IT **90141-22-3, (-)-Gossypol**RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)(glycolytic inhibitory and respiratory uncoupling effects of, on
Ehrlich ascites tumor cells)L26 ANSWER 7 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 88091803 EMBASE

DOCUMENT NUMBER: 1988091803

TITLE: Selective toxicity of gossypol against epithelial tumors
and its detection by magnetic resonance spectroscopy.

AUTHOR: Benz C.; Keniry M.; Goldberg H.

CORPORATE SOURCE: Cancer Research Institute, University of California, San
Francisco, CA, United States

SOURCE: Contraception, (1988) 37/3 (221-228).

ISSN: 0010-7824 CODEN: CCPTAY

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 010 Obstetrics and Gynecology

016 Cancer

028 Urology and Nephrology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The antitumor toxicity of gossypol was measured in 6 human carcinoma cell
lines and compared with its toxicity against human bone marrow stem cells.
Marrow cells were more resistant than any of the tumor cell lines, and

tumor cell sensitivity depended on the content of intracellular LDH-M.
[31P]-Magnetic resonance spectroscopy showed decline in tumor ATP levels
occurring within 24 hours of treatment, suggesting that this non-invasive
technique may serve as an early biochemical monitor of gossypol toxicity.

CT Medical Descriptors:

*cell line

*epithelium tumor

cell culture

nuclear magnetic resonance

priority journal

human cell

human

male

female

Drug Descriptors:

*antineoplastic agent

*gossypol: PD, pharmacology

RN (gossypol) 303-45-7

L26 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:51382 HCAPLUS

DOCUMENT NUMBER: 110:51382

TITLE: Determination of gossypol enantiomers in plasma after
administration of racemate using high-performance
liquid chromatography with precolumn chemical
derivatization

AUTHOR(S): Wu, Da Fang; Reidenberg, Marcus M.; Drayer, Dennis E.

CORPORATE SOURCE: Med. Coll., Cornell Univ., New York, NY, 10021, USA

SOURCE: Journal of Chromatography (1988), 433, 141-8

CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A HPLC assay with precolumn chemical derivatization was developed for the
determination of gossypol enantiomers in plasma, after administration of the
racemate. Racemic gossypol acetic acid in plasma was extracted into
acetonitrile and analyzed using a reversed-phase column and a coulometric
detector in the redox mode. To sep. the enantiomers, 30 µL of the
chiral derivatizing reagent, (R)-(-)-2-amino-1-propanol (50 mg/mL) and 15
µL of 20% (volume/vol) acetic acid were added to the acetonitrile layer
which was then heated at 60° for 100 min. The mobile phase used to
resolve the derivatized enantiomers was 0.2M phosphate buffer (pH
3.5)-acetonitrile (38:62, volume/volume). At a flow rate of 1.5 mL/min, the
retention times for derivatized (+)-gossypol and (-)-gossypol were 4.0 and
7.8 min, resp. Two **cancer** patients received 10 mg racemic
gossypol acetic acid 3 times a day. In 1 patient, the racemic, (+)- and
(-)-gossypol acetic acid plasma concns. after 65 days of therapy were 317,
213, and 104 ng/mL, resp. In the other patient, these values were 362,
210, and 152 ng/mL, resp., after a week of therapy.

CC 2-1 (Mammalian Hormones)

IT 20300-26-9, (+)-Gossypol **90141-22-3**, (-)-Gossypol

RL: ANT (Analyte); ANST (Analytical study)

(determination of, in blood plasma of human by HPLC with precolumn
derivatization)

L26 ANSWER 9 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 87077188 EMBASE

DOCUMENT NUMBER: 1987077188

TITLE: Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123.

AUTHOR: Benz C.; Hollander C.; Keniry M.; et al.

CORPORATE SOURCE: Cancer Research Institute, University of California, San Francisco, CA 94143, United States

SOURCE: Journal of Clinical Investigation, (1987) 79/2 (517-523).
CODEN: JCINAO

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index
029 Clinical Biochemistry
016 Cancer
030 Pharmacology

LANGUAGE: English

AB Three compounds that share specific antimitochondrial properties are gossypol, rhodamine-123, and lonidamine. We compare the antiproliferative activities of these drugs against six human cell lines derived from breast (T47-D), pancreas (MiaPaCa, RWP-2), prostate (DU-145), colon (HCT-8), and cervix (HeLa) carcinomas. Tumor cells enriched in cathodal LDH isozymes (LDH4 and LDH5) are significantly more sensitive to gossypol and rhodamine-123. When compared for ability to inhibit growth of human marrow in soft agar, 10 μ M gossypol shows little effect on colony formation whereas 10 μ M rhodamine-123 completely prevents stem cell growth, suggesting that gossypol may have the most favorable therapeutic index. Within 24 h of drug administration, there is a relative increase in intracellular inorganic phosphate pools and a marked decline in soluble high-energy phosphates in sensitive tumor cells, as measured by 31P magnetic resonance spectroscopy. These studies suggest that specific antimitochondrial agents might be selectively administered on the basis of tumor LDH isozyme content and noninvasively monitored for antiproliferative activity by 31P spectroscopy.

CT Medical Descriptors:

- *breast cancer
- *cell growth
- *colon cancer
- *drug comparison
- *drug cytotoxicity
- *drug efficacy
- *drug interaction
- *drug mechanism
- *nuclear magnetic resonance
- *pancreas cancer
- *prostate cancer
- *uterine cervix cancer
- breast carcinoma
- colon carcinoma
- human cell
- pancreas carcinoma
- prostate carcinoma
- uterine cervix carcinoma
- priority journal
- intoxication
- pancreas
- male genital system
- large intestine
- female genital system
- drug administration

preliminary communication
in vitro study
human
endocrine system
breast

Drug Descriptors:

***gossypol**
*lactate dehydrogenase isoenzyme
***lonidamine**
*rhodamine 123
radioisotope

RN (gossypol) 303-45-7; (lonidamine) 50264-69-2; (rhodamine 123) 62669-70-9
CO Sigma; Angelini (Italy)

L26 ANSWER 10 OF 19 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 87324751 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3631888
TITLE: Influence of 5-hydroxytryptamine on the combination effect
of lonidamine or gossypol and hyperthermia on Ehrlich
tumour in vivo.
AUTHOR: Molla M R; Yoshiga K; Takada K
SOURCE: Anticancer research, (1987 May-Jun) 7 (3 Pt B)
361-4.
Journal code: 8102988. ISSN: 0250-7005.
PUB. COUNTRY: Greece
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198709
ENTRY DATE: Entered STN: 19900305
Last Updated on STN: 19900305
Entered Medline: 19870929
AB An experiment was conducted using lonidamine and gossypol against Ehrlich
tumour in the foot pad of CD-1 mice. These compounds alone were mild
antitumour agents, but their cytotoxicity increased when they were
combined with hyperthermia. The antitumor effect was further increased by
5-hydroxytryptamine, particularly when combined with lonidamine.
CT Check Tags: Male; Support, Non-U.S. Gov't
Animals
***Antineoplastic Combined Chemotherapy Protocols: TU, therapeutic
use**
***Carcinoma, Ehrlich Tumor: TH, therapy**
Combined Modality Therapy
***Gossypol: AD, administration & dosage**
Hydrogen-Ion Concentration
***Hyperthermia, Induced**
***Indazoles: AD, administration & dosage**
Mice
***Pyrazoles: AD, administration & dosage**
***Serotonin: PD, pharmacology**
RN 303-45-7 (Gossypol); 50-67-9 (Serotonin); 50264-69-2 (lonidamine)
CN 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (Indazoles); 0
(Pyrazoles)

L26 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1986:583551 HCAPLUS
DOCUMENT NUMBER: 105:183551
TITLE: Cytotoxicity of enantiomers of gossypol

generation of active oxygen species via redox cycling. Certain quinones have been shown to be mutagenic via the formation of active oxygen species and others via their conversion to DNA-binding semiquinone free radicals. Paradoxically, quinones are not only mutagenic and therefore potentially carcinogenic, they are also effective anticancer agents. Classic examples are Adriamycin (doxorubicin hydrochloride) and mitomycin C, but other less complex quinones also show effective antitumor activity. The design of novel quinones that are more selective in their toxicity to human tumor cells and whose mechanism of action is understood seems a promising approach in cancer treatment, especially if host toxicity can be prevented via the use of chemoprotective agents.

CT

Medical Descriptors:

*2,3 dimethylbenzoquinone

*cancer combination chemotherapy

***chemical carcinogenesis**

*drug toxicity

priority journal

therapy

intoxication

drug administration

short survey

methodology

human

nonhuman

animal

ecology

clinical article

animal cell

Drug Descriptors:

*1 naphthol

***antineoplastic agent**

*benzene

*benzoquinone

*carcinogen

***carmustine**

*catechol

daunorubicin**diethylstilbestrol*****doxorubicin**

*drug metabolite

gossypol**lapachol**

*lawsone

*menadione

***mitomycin c**

*mutagenic agent

***nogalamycin**

*paracetamol

*phenol

*phytomenadione

zorubicin**rufocromomycin****mitomycin**

RN

(1 naphthol) 90-15-3; (benzene) 71-43-2; (carmustine) 154-93-8; (catechol) 120-80-9; (daunorubicin) 12707-28-7, 20830-81-3, 23541-50-6; (diethylstilbestrol) 30498-85-2, 56-53-1; (doxorubicin) 23214-92-8, 25316-40-9; (gossypol) 303-45-7; (lapachol) 84-79-7; (lawsone) 83-72-7; (menadione) 58-27-5; (mitomycin c) 50-07-7, 74349-48-7; (nogalamycin)

*diaphragm
 *gallbladder disease
 *gastrointestinal toxicity
 *headache
 *hypertension
 *intrauterine contraceptive device
 *loestrin 1 20
 *phenoxybenzamine
 *pregnancy
 *progesterone containing intrauterine contraceptive device
 *uterine cervix dysplasia
 priority journal
 female genital system
 breast
 cardiovascular system
 gallbladder
 intoxication
 oral drug administration
 short survey
 human
 prevention

Drug Descriptors:

*conjugated estrogen
 *estrogen
 *ethinylestradiol
 *etynodiol
 *etynodiol diacetate
 *gestagen
 *gonadorelin
 *gossypol
 *ethinylestradiol plus levonorgestrel
 *medroxyprogesterone acetate
 *mestranol
 *norethisterone
 *norethisterone acetate
 *mestranol plus norethisterone
 *norgestrel
 *ethinylestradiol plus norgestrel
 *ethinylestradiol plus norethisterone
 *oral contraceptive agent
 ampicillin
 barbituric acid derivative
 carbamazepine
 chloramphenicol
 ethosuximide
 penicillin g
 phenytoin
 primidone
 rifampicin
 loestrin 1 20
 ethinylestradiol plus etynodiol diacetate
 progesterone
 unclassified drug
 (ethinylestradiol) 57-63-6; (etynodiol) 1231-93-2; (etynodiol diacetate)
 297-76-7; (gonadorelin) 33515-09-2, 9034-40-6; (gossypol) 303-45-7;
 (ethinylestradiol plus levonorgestrel) 39366-37-5; (medroxyprogesterone
 acetate) 71-58-9; (mestranol) 72-33-3; (norethisterone) 68-22-4;
 (norethisterone acetate) 51-98-9; (mestranol plus norethisterone)

RN

8015-29-0; (norgestrel) 6533-00-2; (ethinylestradiol plus norgestrel)
 8056-51-7; (ethinylestradiol plus norethisterone) 37270-71-6; (ampicillin)
 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; (carbamazepine)
 298-46-4, 8047-84-5; (chloramphenicol) 134-90-7, 2787-09-9, 56-75-7;
 (ethosuximide) 77-67-8; (penicillin g) 1406-05-9, 61-33-6; (phenytoin)
 57-41-0, 630-93-3; (primidone) 125-33-7; (rifampicin) 13292-46-1;
 (ethinylestradiol plus etynodiol diacetate) 8075-78-3; (progesterone)
 57-83-0

CN Loestrin 1 20; Norinyl; Ortho novum 777; Depo provera; Nordette;
 Trinorinyl; Ovrette; Demulen; Progestasert; Premarin; Triphasil; Brevicon;
 Ovral; Modicon

L26 ANSWER 15 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 85155611 EMBASE

DOCUMENT NUMBER: 1985155611

TITLE: Antitumor effects of gossypol on murine tumors.

AUTHOR: Rao P.N.; Yong-Chao Wang; Lotzova E.; et al.

CORPORATE SOURCE: Department of Chemotherapy Research, The University of
 Texas M.D. Anderson Hospital and Tumor Institute at
 Houston, Houston, TX 77030, United States

SOURCE: Cancer Chemotherapy and Pharmacology, (1985) 15/1 (20-25).
 CODEN: CCPHDZ

COUNTRY: Germany

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index
 030 Pharmacology
 016 Cancer
 052 Toxicology

LANGUAGE: English

AB Since the male antifertility drug, gossypol, was shown to be a specific
 inhibitor of DNA synthesis at moderately low doses in cultured cells, its
 antitumor potential has been evaluated in three murine tumor models. The
 effects of gossypol on tumor growth and the survival of 10- to 12-week-old
 BDF1 mice bearing mouse mammary adenocarcinoma 755 (Ca 755) or P388 or
 L1210 leukemias, all injected IP, were measured. At an optimum dose of 0.5
 mg/mouse given as a single injection at 2 days (48 h) after the
 inoculation of 105 Ca 755 tumor cells, gossypol rendered 66% of the mice
 free of tumor cells, whereas the remaining 34% died of drug toxicity. The
 survival rate decreased sharply at doses on either side of the optimum. At
 suboptimal doses a major proportion of the tumor-bearing mice died of
 tumor, whereas at higher doses all the animals died of drug toxicity. In
 other words, the effective dose range of gossypol was rather narrow. The
 rapidly proliferating mouse leukemias, P388 and L1210, failed to respond
 to gossypol. Histopathological studies of various organs in the
 gossypol-treated mice revealed no consistent lesions that could give an
 indication of organ-specific toxicity of gossypol. The reduction in the
 myeloid series in the bone marrow of gossypol-treated mice may have been
 due to depletion rather than direct toxic effect. Further studies are
 essential to evaluate this compound with regard to its antitumor activity
 in other murine models.

CT Medical Descriptors:

*breast cancer
 *cancer cell culture
 *cancer chemotherapy
 *cancer growth
 *drug efficacy
 *drug toxicity

***leukemia**

histopathology
 mouse
 priority journal
 therapy
 intoxication
 intraperitoneal drug administration
 methodology
 nonhuman
 animal experiment
 animal model
 Drug Descriptors:

antineoplastic agent**gossypol**

RN (gossypol) 303-45-7
 CO Southwest research foundation (United States)

L26 ANSWER 16 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 85021195 EMBASE
 DOCUMENT NUMBER: 1985021195
 TITLE: [Genital virus infections. Their treatment].
 LES VIROSES GENITALES. A PROPOS DE LEUR TRAITEMENT.
 AUTHOR: Legros R.; Coupez F.; Louis E.
 CORPORATE SOURCE: Service de Gynecologie Chirurgicale et de Senologie, Centre
 Hospitalier, F 94010 Creteil Cedex, France
 SOURCE: Gynecologie, (1984) 35/4 (303-311).
 CODEN: GYNCAZ
 COUNTRY: France
 DOCUMENT TYPE: Journal
 FILE SEGMENT: 037 Drug Literature Index
 010 Obstetrics and Gynecology
 047 Virology
 013 Dermatology and Venereology
 030 Pharmacology
 LANGUAGE: French
 SUMMARY LANGUAGE: English

AB The treatment of condylomas of the uterine cervix occupies a justified place amongst current preoccupations in gynaecology. The role of the CO2 laser is preponderant but not unique. The authors report on this study their experience based upon 169 of condylomas. However HPV virus infections account for only a proportion of genital virus disorders and the local treatment of condylomas cannot alone cover all therapeutic possibilities. Even if results obtained by medical methods are often disappointing, they must nevertheless be analysed and their limitations assessed. The existence of a virus infection during pregnancy requires special management, above all because of possible consequences for the newborn infant. The selection of populations with a greater oncogenic risk is possible. This is progress of great interest whilst awaiting the day when the vaccination of young patients will become possible.

CT Medical Descriptors:

***condyloma**

*genital tract infection
 *genital herpes
 *herpes simplex virus 2
 *papilloma virus
 *drug therapy
 laser

pregnancy

therapy

human

Drug Descriptors:

*fiacitabine

*aciclovir

*azathioprine

*bleomycin

*5 (2 bromovinyl) 2' deoxyuridine

*colchicine

*fluorouracil

*gossypol

*herpes vaccine

*idoxuridine

*interferon

*methisoprinol

*foscarnet

*podophyllin

*trifluridine

*vidarabine

RN (fiacitabine) 69123-90-6; (aciclovir) 59277-89-3; (azathioprine) 446-86-6; (bleomycin) 11056-06-7; (5 (2 bromovinyl) 2' deoxyuridine) 69304-47-8, 82768-44-3; (colchicine) 64-86-8; (fluorouracil) 51-21-8; (gossypol) 303-45-7; (idoxuridine) 54-42-2; (methisoprinol) 36703-88-5; (foscarnet) 4428-95-9; (podophyllin) 9000-55-9; (trifluridine) 70-00-8; (vidarabine) 2006-02-2, 5536-17-4

CN Imurel; Zovirax; Iduviran

L26 ANSWER 17 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 84102554 EMBASE

DOCUMENT NUMBER: 1984102554

TITLE: The effect of gossypol and lonidamine on electron transport in Ehrlich ascites tumor mitochondria.

AUTHOR: Floridi A.; D'Atri S.; Bellocci M.; et al.

CORPORATE SOURCE: Regina Elena Institute for Cancer Research, 00161 Rome, Italy

SOURCE: Experimental and Molecular Pathology, (1984) 40/2 (246-261).

CODEN: EXMPA6

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index
005 General Pathology and Pathological Anatomy
030 Pharmacology
048 Gastroenterology
016 Cancer

LANGUAGE: English

AB The effect of the association of gossypol and Lonidamine on the electron transport in Ehrlich ascites tumor mitochondria has been investigated by addition of drugs to isolated mitochondria. The results may be summarized as follows. (1) Low concentrations of gossypol increase the rate of oxygen consumption at the level of three energy-conserving sites of the respiratory chain. Higher concentrations result in an inhibition of oxygen consumption at (or near) both energy-conserving sites 1 and 2, while energy-conserving site 3 is unaffected. (2) Gossypol, at concentrations at which it exerts its uncoupling effect, stimulates ATPase activity. Higher concentrations inhibit the enzyme activity. (3) The addition of gossypol

to mitochondria respiring on pyruvate plus malate or succinate induces a more oxidized state of NAD⁺ and cytochrome b, respectively. (4) gossypol enhances the effect of Lonidamine on oxygen consumption. Lonidamine does not affect state 4 respiration, but in the presence of gossypol, it determines a marked decrease in the rate of oxygen consumption. The inhibition of oxidation of NAD-linked substrates is greater than that of FAD-linked substrates. (5) It may be concluded that gossypol is very effective in potentiating the effect of Lonidamine. Moreover, it may be suggested that the antitumor activity of Lonidamine is enhanced if it is used in combination with other drugs and/or treatments, such as hyperthermia, which modify the energy status of mitochondria.

CT Medical Descriptors:

*cancer cell
 *ehrlich ascites tumor
 *electron transport
 *mitochondrion
 *oxygen consumption
 cancer chemotherapy
 ehrlich ascites
 nonhuman
 therapy
 Drug Descriptors:
 *adenosine triphosphatase
 *gossypol
 *lonidamine
 enzyme

RN (adenosine triphosphatase) 37289-25-1, 9000-83-3; (gossypol) 303-45-7;

(lonidamine) 50264-69-2

CO Poliscience (United States)

L26 ANSWER 18 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 83232276 EMBASE

DOCUMENT NUMBER: 1983232276

TITLE: Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases.

AUTHOR: Ames B.N.

CORPORATE SOURCE: Dep. Biochem., Univ. California, Berkeley, CA 94720, United States

SOURCE: Science, (1983) 221/4617 (1256-1263).

CODEN: SCIEAS

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index
 017 Public Health, Social Medicine and Epidemiology
 052 Toxicology
 030 Pharmacology
 016 Cancer

LANGUAGE: English

AB The human diet contains a great variety of natural mutagens and carcinogens, as well as many natural antimutagens and anticarcinogens. Many of these mutagens and carcinogens may act through the generation of oxygen radicals. Oxygen radicals may also play a major role as endogenous initiators of degenerative processes, such as DNA damage and mutation (and promotion), that may be related to cancer, heart disease, and aging. Dietary intake of natural antioxidants could be an important aspect of the body's defense mechanism against these agents. Many antioxidants are being identified as anticarcinogens. Characterizing and optimizing such defense

systems may be an important part of a strategy of minimizing cancer and other age-related diseases.

CT Medical Descriptors:

*age
 ***cancer**
 *chaconine
 ***chemical carcinogenesis**
 *convicine
 *dna damage
 *dna synthesis
 *diet
 *drug toxicity
 *heart disease
 *malvalic acid
 *methyleugenol
 *mutation
 *sterculic acid
 *vicine
 aging
 heart
 intoxication
 review
 human
 etiology

Drug Descriptors:

*allyl isothiocyanate
 *alpha tocopherol
 *anagyrrine
 ***antineoplastic agent**
 *ascorbic acid
 *beta carotene
 *canavanine
 *carcinogen
 *estragole
 *alcohol
 *glutathione
 ***gossypol**
 *lactone derivative
 *mutagenic agent
 *oxygen radical
 *phorbol ester
 *psoralen derivative
 *pyrrolizidine derivative
 *quercetin
 *quinone derivative
 *safrole
 *selenium
 *solanine
 *theobromine
 *uric acid

antimutagenic agent

antioxidant

RN (allyl isothiocyanate) 57-06-7; (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (anagyrrine) 486-89-5; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (beta carotene) 7235-40-7; (canavanine) 543-38-4; (estragole) 140-67-0; (alcohol) 64-17-5; (glutathione) 70-18-8; (gossypol) 303-45-7; (quercetin) 117-39-5; (safrole) 94-59-7; (selenium) 7782-49-2; (solanine) 20562-02-1, 51938-42-2; (theobromine) 83-67-0; (uric

acid) 69-93-2

L26 ANSWER 19 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 83198979 EMBASE
DOCUMENT NUMBER: 1983198979
TITLE: The effect of the association of gossypol and lonidamine on
the energy metabolism of Ehrlich ascites tumor cells.
AUTHOR: Floridi A.; D'Atri S.; Menichini R.; et al.
CORPORATE SOURCE: Reginal Elena Inst. Cancer Res., 00161 Rome, Italy
SOURCE: Experimental and Molecular Pathology, (1983) 38/3
(322-335).
CODEN: EXMPA6
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
005 General Pathology and Pathological Anatomy
029 Clinical Biochemistry
048 Gastroenterology
016 Cancer
030 Pharmacology
LANGUAGE: English

AB The effect of the association of Gossypol and Lonidamine on the energy metabolism of Ehrlich ascites tumor cells has been investigated. The action of the drug on tumor cells was studied by addition of the drugs to cells harvested from Swiss male mice. The results may be summarized as follows: (1) Low concentrations of gossypol increase the rate of oxygen consumption by uncoupling oxidative phosphorylation. High concentrations result in an inhibition of oxygen consumption with a mechanism that must be regarded as not directly related to the uncoupling activity. (2) Gossypol, at concentrations at which it exerts an uncoupling activity, stimulates mitochondrial ATPase which in turn increases the aerobic and anaerobic rates of lactate production. The decrease of glycolysis at high concentrations of Gossypol does not depend on the inhibition of enzymes of the glycolytic pathway, but must be ascribed to cell death. (3) The association of a low concentration of Gossypol with Lonidamine brings about a further inhibition of oxygen consumption. Moreover, Lonidamine abolishes the stimulation of glycolysis induced by Gossypol and lowers lactate production to values that are quite similar to those found with Lonidamine alone. (4) It may be concluded that the association of Gossypol and Lonidamine results in a very effective decrease of the energy requirements of cancer cells.

CT Medical Descriptors:
*ascites
*cancer cell
*drug efficacy
*ehrlich ascites tumor cell
*energy transfer
*tumor cell
mouse
oxygen consumption
nonhuman
blood and hemopoietic system
in vitro study
Drug Descriptors:
*gossypol
*lonidamine
*oligomycin

*ouabain
lactic acid
proton transporting adenosine triphosphate synthase
RN (gossypol) 303-45-7; (lonidamine) 50264-69-2; (oligomycin) 1404-19-9;
(ouabain) 11018-89-6, 630-60-4; (lactic acid) 113-21-3, 50-21-5; (proton
transporting adenosine triphosphate synthase) 37205-63-3

=> b home

FILE 'HOME' ENTERED AT 13:25:05 ON 24 NOV 2004

=>



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



1404-15-5; (paracetamol) 103-90-2; (phenol) 108-95-2, 3229-70-7;
(phytomenadione) 11104-38-4, 84-80-0; (zorubicin) 36508-71-1, 54083-22-6;
(rufocromomycin) 11031-41-7, 3930-19-6; (mitomycin) 1404-00-8

L26 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1986:199755 HCAPLUS

DOCUMENT NUMBER: 104:199755

TITLE: Comparison of action of racemic (\pm) and optically active (- and +) gossypols on HeLa cells

AUTHOR(S): Zhang, Jingbo; Zhang, Shifu; Yuan, Ju; Xu, Kaiming

CORPORATE SOURCE: Inst. Basic Med. Sci., Chin. Acad. Med. Sci., Beijing, Peop. Rep. China

SOURCE: Zhongguo Yixue Kexueyuan Xuebao (1985), 7(5), 384-7

CODEN: CIHPDR; ISSN: 0253-3774

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB In HeLa cell cultures, (-)-gossypol [90141-22-3] and (\pm)-gossypol [40112-23-0] inhibited the cell growth, DNA synthesis, and cell division, whereas (+)-gossypol [20300-26-9] had no effect. The effective concentration of the (-)-isomer is 2-fold less than that of racemic gossypol, suggesting that the antitumor activity of racemic gossypol is due to the (-)-isomer.

CC 1-6 (Pharmacology)

IT **Neoplasm inhibitors**
(gossypol isomers as)

IT 303-45-7 20300-26-9 **90141-22-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm-inhibiting activity of)

L26 ANSWER 14 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 86030718 EMBASE

DOCUMENT NUMBER: 1986030718

TITLE: Prescription contraceptives: Countering the risks.

AUTHOR: Ruggiero R.J.

CORPORATE SOURCE: Division of Clinical Pharmacy, Department of Pharmaceutical Services, University of California, Los Angeles, CA, United States

SOURCE: American Pharmacy, (1985) 25/9 (32-37).

CODEN: AMPHDF

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 038 Adverse Reactions Titles

037 Drug Literature Index

LANGUAGE: English

CT Medical Descriptors:

*adverse drug reaction

*breakthrough bleeding

***breast cancer**

*breast feeding

*mastalgia

***carcinogenesis**

*candidiasis

*cardiovascular disease

*contraception

AUTHOR(S): Joseph, A. E. A.; Matlin, S. A.; Knox, P.
CORPORATE SOURCE: Dep. Radiol., St. George's Hosp., London, SW17 0QT, UK
SOURCE: British Journal of Cancer (1986), 54(3),
511-13
CODEN: BJCAAI; ISSN: 0007-0920

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Racemic gossypol [40112-23-0] inhibited proliferation of both normal fibroblasts and tumor-derived cells. (-)-Gossypol [90141-22-3] was much more cytotoxic than was (+)-gossypol [20300-26-9], a difference similar to that reported for production of infertility. A (-)-gossypol concentration

of 1.9 µg/mL caused a 50% reduction in cell growth of human fibroblasts, and 50% cell lysis was attained with .apprx.10 µg gossypol/mL. Although cell lysis did not become visible for .apprx.16 h, a 30-min exposure time was adequate to induce the cytolytic effect. The cytotoxicity of gossypol was diminished as a result of binding by plasma proteins, which may account for the low incidence of side effects in clin. antifertility studies.

CC 1-6 (Pharmacology)

Section cross-reference(s): 2

IT **Neoplasm inhibitors**

(gossypol and gossypol enantiomers as)

IT 303-45-7 20300-26-9 **90141-22-3**

RL: PRP (Properties)

(cytotoxicity of, in fibroblast and tumor-derived cells)

L26 ANSWER 12 OF 19 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 86104334 EMBASE

DOCUMENT NUMBER: 1986104334

TITLE: Quinones as mutagens, carcinogens, and anticancer agents:
Introduction and overview.

AUTHOR: Smith M.T.

CORPORATE SOURCE: Department of Biomedical and Environmental Health Sciences,
School of Public Health, University of California,
Berkeley, CA 94720, United States

SOURCE: Journal of Toxicology and Environmental Health, (1985) 16/5
(665-672).

CODEN: JTEHD6

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index
052 Toxicology
016 Cancer
030 Pharmacology
017 Public Health, Social Medicine and Epidemiology
025 Hematology
035 Occupational Health and Industrial Medicine
006 Internal Medicine

LANGUAGE: English

AB Quinones are widespread in our environment, occurring both naturally and as pollutants. Human exposure to them is therefore extensive. Quinones also form an important class of toxic metabolites generated as a result of the metabolism of phenols and related compounds, including phenol itself, 1-naphthol, and diethylstilbesterol. The mechanisms by which quinones exert their toxic effect are complex, but two processes appear to be centrally involved: the direct arylation of sulfhydryls, and the

pentose-phosphate shuttle is an important source of reducing equivalents in T47-D cells. This pathway may prove to be a useful target for site-directed drug attack in carcinoma cell lines that require large quantities of NADP for the synthesis of fatty acids and steroids.

CT Medical Descriptors:

*cell metabolism

*tumor cell

nuclear magnetic resonance

priority journal

Drug Descriptors:

*6 aminonicotinamide: PD, pharmacology

*gossypol: PD, pharmacology

RN (6 aminonicotinamide) 329-89-5; (gossypol) 303-45-7

CO Sigma

L26 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:165719 HCAPLUS

DOCUMENT NUMBER: 110:165719

TITLE: Antiproliferative effect of gossypol and its optical isomers on human reproductive **cancer** cell lines

AUTHOR(S): Band, Vimla; Hoffer, Anita P.; Bands, Hamid; Rhinehardt, Ann E.; Knapp, Robert C.; Matlin, Stephen A.; Anderson, Deborah J.

CORPORATE SOURCE: Dana Farber Cancer Inst., Harvard Med. Sch., Boston, MA, 02115, USA

SOURCE: Gynecologic Oncology (1989), 32(3), 273-7

CODEN: GYNOA3; ISSN: 0090-8258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antiproliferative effect of gossypol and its optical isomers on various human cell lines of reproductive and nonreproductive tissue origin was studied. Various reproductive **cancer** cell lines of ovarian, gestational, and testicular origin were highly sensitive (IC50 values of 0.86-1.98 µg/mL) to gossypol. The antiproliferative action of gossypol was not restricted to reproductive **cancers**, as nonreproductive **cancer** cell lines were also equally sensitive (IC50 values of 0.69-3.55 µg/mL). In addition, actively proliferating untransformed cells such as fibroblasts and PHA-activated lymphocytes were also sensitive (IC50 values of 0.87-2.51 µg/mL). (-)-Gossypol was 3.6-12.4 times more potent than (+)-gossypol and 1.48-2.65 times more potent than (±)-gossypol. The most sensitive indicator of gossypol action was a decrease in DNA synthesis, followed by inhibition of protein synthesis and uptake of rhodamine-123 by mitochondria, as tested in an ovarian **cancer** cell line (OVCA 433) and a fibroblast line (Hs27). Gossypol possesses a general nonselective antiproliferative action toward human cells in vitro. Further, the pharmacol. activity of gossypol as an antiproliferative agent is primarily attributable to its (-) isomer, which is also the active isomer as a contraceptive.

CC 1-6 (Pharmacology)

Section cross-reference(s): 2

ST gossypol gonadal **cancer**; cell proliferation gossypol isomer

IT **Neoplasm inhibitors**

(gossypol isomer as, for gonadal cells)

IT 303-45-7, (±)-Gossypol 20300-26-9, (+)-Gossypol 90141-22-3,

(-)-Gossypol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

L21 (495) SEA FILE=MEDLINE ABB=ON PLU=ON L19/MAJ)
L22 (365762) SEA FILE=MEDLINE ABB=ON PLU=ON L20/MAJ)
L23 (17) SEA FILE=MEDLINE ABB=ON PLU=ON L21 AND L22
L24 (17) SEA FILE=MEDLINE ABB=ON PLU=ON L23 AND PY<=2004
L25 4 SEA FILE=MEDLINE ABB=ON PLU=ON L24 AND PY<=1990

*/MAJ here and in
EMBASE indicates
a "major descriptor",
i.e. the main point
of the article*

=> b embase

FILE 'EMBASE' ENTERED AT 13:24:15 ON 24 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 19 Nov 2004 (20041119/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d que l11

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON "(-)-GOSSYPOL"/CN
L2 1036 SEA FILE=EMBASE ABB=ON PLU=ON GOSSYPOL/CT OR L1
L3 838 SEA FILE=EMBASE ABB=ON PLU=ON L2/MAJ
L5 564986 SEA FILE=EMBASE ABB=ON PLU=ON "ANTINEOPLASTIC AGENT"+NT/CT
L6 372774 SEA FILE=EMBASE ABB=ON PLU=ON L5/MAJ
L7 77 SEA FILE=EMBASE ABB=ON PLU=ON L3 AND L6
L8 1241999 SEA FILE=EMBASE ABB=ON PLU=ON NEOPLASM+NT/CT
L9 1041317 SEA FILE=EMBASE ABB=ON PLU=ON L8/MAJ
L10 14 SEA FILE=EMBASE ABB=ON PLU=ON L7 AND L9
L11 11 SEA FILE=EMBASE ABB=ON PLU=ON L10 AND PY<=1990

=> dup rem l25 l11 l18

FILE 'MEDLINE' ENTERED AT 13:24:34 ON 24 NOV 2004

FILE 'EMBASE' ENTERED AT 13:24:34 ON 24 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 13:24:34 ON 24 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L25

PROCESSING COMPLETED FOR L11

PROCESSING COMPLETED FOR L18

L26 19 DUP REM L25 L11 L18 (2 DUPLICATES REMOVED)

=> d ibib abs hitind l26 1-19

L26 ANSWER 1 OF 19 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 90294807 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2193225
TITLE: Biochemical correlates of the antitumor and
antimitochondrial properties of gossypol enantiomers.
AUTHOR: Benz C C; Keniry M A; Ford J M; Townsend A J; Cox F W;
Palayoor S; Matlin S A; Hait W N; Cowan K H
CORPORATE SOURCE: Cancer Research Institute, University of California, San
Francisco 94143.

Searched by P. Ruppel

CONTRACT NUMBER: CA46966 (NCI)
SOURCE: Molecular pharmacology, (1990 Jun) 37 (6) 840-7.
Journal code: 0035623. ISSN: 0026-895X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199008
ENTRY DATE: Entered STN: 19900907
Last Updated on STN: 19980206
Entered Medline: 19900801

AB Racemic gossypol has been shown to have antitumor properties that may be due to its ability to uncouple tumor mitochondria or to its inhibitory effects on a variety of nonmitochondrial enzymes. We have studied the antimitochondrial and enzyme-inhibiting properties of gossypol in human carcinoma cell lines of breast (MCF-7, T47-D), ovarian (OVCAR-3) colon (HCT-8), and pancreatic (MiaPaCa) origin by comparing the effects of its purified (+)- and (-)-enantiomers. (-)-Gossypol shows up to 10-fold greater antiproliferative activity than (+)-gossypol in the cancer cell lines and in normal hematopoietic stem cells grown in vitro, with IC50 values ranging from 1.5 to 4.0 microM for the cancer cells and from 10 to 20 microM for the human marrow stem cells. As well, multidrug-resistant MCF/Adr cells appear more resistant to (-)-gossypol than their parental cell line. Electron microscopy indicates that the earliest ultrastructural change in tumor cells exposed to a cytotoxic (10 microM) concentration of (-)-gossypol is the selective destruction of their mitochondria. Consistent with this observation, 31P magnetic resonance spectroscopy detects pronounced changes in tumor cell high energy phosphate metabolism within 24 hr of (-)-gossypol treatment, manifest by 1.6- to greater than 50-fold differential reductions in the intracellular ratios of ATP/Pi, relative to (+)-gossypol-treated cell lines; the magnitude of these antimitochondrial effects correlates with the antiproliferative activity of (-)-gossypol. Northern blot RNA analyses suggest that treatment with a 5-10 microM dose of (-)-gossypol induces a transient increase in the expression of heat shock gene products, particularly hsp-70 transcripts. The mean 5-fold increase in (-)-gossypol-induced hsp-70 mRNA appears coincident with a comparable heat-stimulated increase in transcript levels, as compared with control or (+)-gossypol-treated cells. The enzyme-inhibiting properties of gossypol enantiomers were compared in cell-free assays measuring glutathione-S-transferase-alpha, -mu, and pi activities, calmodulin stimulation of cyclic nucleotide phosphodiesterase, and protein kinase C activity. Both enantiomers are near equivalent antagonists of calmodulin stimulation and protein kinase C activity, exceeding the potency of known inhibitors such as phenothiazines by as much as 50-fold. In contrast, (-)-gossypol is a 3-fold more potent inhibitor of glutathione-S-transferase-alpha and -pi isozyme activity, resulting in IC50 values of 1.6 and 7.0 microM, respectively, for these two isozymes. (ABSTRACT TRUNCATED AT 400 WORDS)

CT Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

***Antineoplastic Agents**

Calmodulin: PD, pharmacology

Glutathione Transferase: ME, metabolism

***Gossypol: PD, pharmacology**

Heat-Shock Proteins: BI, biosynthesis

Heat-Shock Proteins: GE, genetics

Isoenzymes: ME, metabolism

*Mitochondria: DE, drug effects